NEW YORK – Immunocore on Tuesday said it began testing its engineered T-cell engager IMC-R117C in patients with PIWIL1-positive colorectal and other cancers in a Phase I/II trial. Immunocore developed ...

Plus, news about Foghorn Ther­a­peu­tics, In­cyte, BioN­Tech, Gal­der­ma, Basilea, In­novia, Pharm­ing, bit.bio, Promise Bio, Out­look Ther­a­peu­tics and Tre­vi Ther­a­peu­tics: ...

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases.

1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Andrea C. Baines, Office of Oncologic ...